BACKGROUND: The synthetic 4'-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette (ABC) proteins P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1). We compared its uptake and cytotoxicity with those of doxorubicin and daunorubicin in cell lines overexpressing Pgp, MRP-1 or breast cancer resistance protein (BCRP) and in acute myeloid leukemia (AML) cells. METHODS: Cellular uptake was studied by flow cytometry and cytotoxicity in 96-h 96-well cultures in cell lines overexpressing Pgp, MRP-1 or wild type (BCRP(R482)) or mutant (BCRP(R482T), BCRP(R482G)) BCRP and in pre-treatment AML marrow cells. RESULTS: Uptake and cytotoxicity of WP744 were consistently greater than those of doxorubicin and daunorubicin at equimolar concentrations in all cell lines studied and in AML cells. CONCLUSION: WP744 overcomes transport by Pgp, MRP-1 and BCRP in cell lines and AML cells and is a promising agent for clinical development in AML and other malignancies with broad-spectrum multidrug resistance.
BACKGROUND: The synthetic 4'-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette (ABC) proteins P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1). We compared its uptake and cytotoxicity with those of doxorubicin and daunorubicin in cell lines overexpressing Pgp, MRP-1 or breast cancer resistance protein (BCRP) and in acute myeloid leukemia (AML) cells. METHODS: Cellular uptake was studied by flow cytometry and cytotoxicity in 96-h 96-well cultures in cell lines overexpressing Pgp, MRP-1 or wild type (BCRP(R482)) or mutant (BCRP(R482T), BCRP(R482G)) BCRP and in pre-treatment AML marrow cells. RESULTS: Uptake and cytotoxicity of WP744 were consistently greater than those of doxorubicin and daunorubicin at equimolar concentrations in all cell lines studied and in AML cells. CONCLUSION: WP744 overcomes transport by Pgp, MRP-1 and BCRP in cell lines and AML cells and is a promising agent for clinical development in AML and other malignancies with broad-spectrum multidrug resistance.
Authors: Y Honjo; C A Hrycyna; Q W Yan; W Y Medina-Pérez; R W Robey; A van de Laar; T Litman; M Dean; S E Bates Journal: Cancer Res Date: 2001-09-15 Impact factor: 12.701
Authors: Misbah Qadir; Kieran L O'Loughlin; Stacy M Fricke; Nicole A Williamson; William R Greco; Hans Minderman; Maria R Baer Journal: Clin Cancer Res Date: 2005-03-15 Impact factor: 12.531
Authors: Attaya Suvannasankha; Hans Minderman; Kieran L O'Loughlin; Takeo Nakanishi; Laurie A Ford; William R Greco; Meir Wetzler; Douglas D Ross; Maria R Baer Journal: Br J Haematol Date: 2004-11 Impact factor: 6.998
Authors: Takeo Nakanishi; Judith E Karp; Ming Tan; L Austin Doyle; Todd Peters; Weidong Yang; David Wei; Douglas D Ross Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: A Suvannasankha; H Minderman; K L O'Loughlin; T Nakanishi; W R Greco; D D Ross; M R Baer Journal: Leukemia Date: 2004-07 Impact factor: 11.528
Authors: Tracy A Brooks; Hans Minderman; Kieran L O'Loughlin; Paula Pera; Iwao Ojima; Maria R Baer; Ralph J Bernacki; Tracy Brooks Journal: Mol Cancer Ther Date: 2003-11 Impact factor: 6.261